We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Change of Nerve Conduction Properties in IVIg Dependent Neuropathies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01655394
Recruitment Status : Unknown
Verified December 2014 by Helmar Lehmann, University of Cologne.
Recruitment status was:  Active, not recruiting
First Posted : August 1, 2012
Last Update Posted : December 12, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored.

Condition or disease
Guillain-Barre Syndrome CIDP Multifocal Motor Neuropathy

Detailed Description:
IVIg exert a variety of different immunomodulatory effects and several mechanism of action have been proposed for IVIg. In this study the role of IVIg on short term nerve conduction in patients with immune-mediated neuropathies will be explored

Study Design

Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
Study Start Date : October 2012
Primary Completion Date : December 2014
Estimated Study Completion Date : June 2016


Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. Clinical Improvement [ Time Frame: 6 Months ]

Biospecimen Retention:   Samples Without DNA
Serum

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with immune neuropathies
Criteria

Inclusion Criteria:

  • immune neuropathy
  • age above 18 y
  • IVIg treatment

exclusion:

  • no IVIg treatment
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655394


Locations
Germany
University of Cologne
Cologne, Germany
Sponsors and Collaborators
University of Cologne
Investigators
Principal Investigator: Helmar C. Lehmann, PD Dr. med. PI
More Information

Responsible Party: Helmar Lehmann, PD Dr. med. H. Lehmann, University of Cologne
ClinicalTrials.gov Identifier: NCT01655394     History of Changes
Other Study ID Numbers: 01607831337
First Posted: August 1, 2012    Key Record Dates
Last Update Posted: December 12, 2014
Last Verified: December 2014

Additional relevant MeSH terms:
Guillain-Barre Syndrome
Polyradiculoneuropathy
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Polyneuropathies
Autoimmune Diseases
Immune System Diseases